Sirtex

February 14, 2020 —  Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced a ...

Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. This designation denotes there is uniform consensus among the NCCN panel that selective internal radiation therapy (SIRT) with yttrium-90 microspheres is an appropriate option in patients with liver dominant, chemotherapy resistant colorectal disease (mCRC). This recommendation places SIR-Spheres Y-90 resin microspheres at the same designation as the recommended mCRC systemic chemotherapeutic regimens.

October 1, 2014 — Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolization, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumor progression" in mCRC patients who have failed to respond to available chemotherapy options.